Related to Unigene and GSK Broaden Deal in Anticipation of Phase III Trial in Postmenopausal Osteoporosis

• CDP Program Moves Deprioritized Candidates into Clinical Trials
  
• GSK and Concert Forge $1B Alliance for Deuterium-Modified Drugs
  
• GSK Nixes $1B Cancer Deal with Synta
  
• GSK Signs On Chroma for Macrophage-Targeted Drug Development
  
• Galapagos Achieves $7.3M Milestone in Osteoarthritis Deal with GSK
  
• Vernalis Earns $6M Up Front in Oncology Deal with GSK
  
• GSK Puts Down $25M for Prosensa’s Mid-Stage Candidate for Duchenne Muscular Dystrophy
  
• GSK to Exploit SuperGen’s Epigenetics Expertise in Cancer Collaboration
  
• GSK Signs On Astex in Broad Partnership for About $33M Up Front
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Galapagos Achieves $5.9M Milestone in Arthritis Deal with GSK
  
• GSK Pays Galapagos $9.45M to Broaden Scope of Arthritis Deal
  
• Seattle Genetics Receives $12M Up Front in Deal with GSK
  
• GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidate
  
• Dynavax and GSK Choose Clinical Candidate from Endosomal TLR Inhibitor Program
  
• GSK and Regulus to Collaborate on miRNA-Based HCV Drugs
  
• Cellzome Pockets $33M Up Front in Second Drug Discovery Collaboration with GSK for Inflammatory Diseases
  
• GSK to Use Horizon Discovery’s Cell Lines for Cancer-Related Metabolomics Research
  
• GSK to Use Gentronix’ GreenScreen HC and BlueScreen HC Genotoxicity Assays
  
• Human Genome Sciences and GSK’s Lupus Candidate Hits the Mark in Second Phase III Trial